What is the impact of bimekizumab on uveitis rates in patients with PsA?

PsOPsA Hub Steering Committee member Peter Nash, Griffith University, Queensland, AU, spoke with Irene van der Horst-Bruinsma, Radboud University Medical Centre, Nijmegen, NL, at the American College of Rheumatology (ACR) Convergence 2025, Oct 24–29, 2025, Chicago, US. They discussed uveitis occurrence in patients with psoriatic arthritis (PsA) receiving bimekizumab across pooled phase IIb and phase III studies.¹ 

Van der Horst-Bruinsma introduced bimekizumab as an interleukin (IL)-17A and -17F inhibitor, and explained that, across placebo-controlled trials, the uveitis exposure-adjusted incidence rate (EAIR) in patients with PsA receiving placebo was high, at 15.4/100 patient-years (PY). However, at 3 years, the uveitis EAIR in patients who received bimekizumab was greatly reduced, to 0.1/100 PY.¹ She highlighted that drugs that inhibit IL-17A only are not effective at reducing uveitis rates.¹